Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athira Pharma Inc ATHA

Healthcare
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline consists of both blood brain barrier permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system, and other indications. Its lead candidate... see more

Recent & Breaking News (NDAQ:ATHA)

Athira Pharma Announces Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire February 10, 2021

Athira Pharma Announces Pricing of Public Offering of Common Stock

GlobeNewswire January 20, 2021

Athira Pharma Announces Proposed Public Offering of Common Stock

GlobeNewswire January 19, 2021

Athira Pharma to Present at the 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2021

Athira Pharma Announces Appointment of Kelly A. Romano to its Board of Directors

GlobeNewswire December 14, 2020

Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer's Disease

GlobeNewswire December 8, 2020

Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimer's Disease

GlobeNewswire December 1, 2020

Athira Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights

GlobeNewswire November 12, 2020

Athira Pharma to Present at Upcoming November Investor Conferences

GlobeNewswire November 10, 2020

Athira Pharma to Host Educational Webinar on the Predictive Nature of P300 to Determine Clinical Benefit of Alzheimer's Disease Treatments

GlobeNewswire October 21, 2020

Lumen Bioscience Announces Appointment of Dr. Mark Litton to Board of Directors

PR Newswire October 8, 2020

Athira Pharma Announces Initiation of Patient Dosing for the LIFT-AD Study, a Phase 2/3 Clinical Trial to Evaluate ATH-1017 for Treatment of Mild-to-Moderate Alzheimer's Disease

GlobeNewswire October 1, 2020

Athira Pharma Announces Closing of Initial Public Offering

GlobeNewswire September 22, 2020

Athira Pharma Announces Pricing of Initial Public Offering

GlobeNewswire September 17, 2020